Disclosures: Jacob Romano: Nothing to Disclose, Jessica Burnside: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor, Alnoor Ramji: Nothing to Disclose, Mark Swain: Ipsen: Advisor, Abbott: Advisor, Advanz: Advisor, Novo Nordisk: Advisor, GSK: Advisor, Ipsen: clinical trial research grant support, Novo Nordisk: clinical trial research grant support, Madrigal: clinical trial research grant support, Kowa: clinical trial research grant support, Gilead: clinical trial research grant support, Abbvie: clinical trial research grant support, Merck: clinical trial research grant support, Galectin: clinical trial research grant support, Sahar Saeed: Novo Nordisk: Consultant 1200 HELICOBACTER PYLORI CAGA/VACAS1-M1 STRAIN IS ASSOCIATED WITH HIGH RISK OF FIBROSIS IN METABOLIC-DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Fernando Barreyro 1 Facundo Maiorana 1 Magali Neschuk 1 Maria Viriginia Caronia 1 Karina Elizondo 2 Adolfo Schneider 2 Georgina Veron 2 Pedro Dario Zapata 1 , 1 National University of Misiones, 2 Barcelo University Institute of Health Sciences Background: Recent studies have suggested an association between H
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Unlike weekly GLP-1 medications, liraglutide is taken once daily, offering consistent, steady support for appetite regulation and metabolic health
How long does it take to see weight loss results with Strive semaglutide
This story was reported from Los Angeles
